{
  "abstract": "Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder worldwide, reflecting the growing prevalence of obesity and type 2 diabetes. Some patients progress to metabolic dysfunction-associated steatohepatitis (MASH), which is linked to cirrhosis, liver failure and hepatocellular carcinoma. The recent approval of resmetirom and semaglutide1 2 for active, fibrotic MASH (F2–F3) highlights the urgent need for accurate, non-invasive tests (NITs). Current guidelines recommend using tools such as the FIB-4 index and liver stiffness measurement by vibration-controlled transient elastography (VCTE) to rule out/rule in advanced fibrosis. However, these NITs have limited ability to identify patients with fibrotic MASH who may be prioritised for novel pharmacological therapies.3 4",
  "authors": [
    {
      "affiliations": [
        "Hepatologie, Hopital Beaujon Service d’hepatologie, Clichy, France"
      ],
      "name": "Laurent Castera"
    }
  ],
  "title": "Thrombospondin-2: a promising but unproven biomarker for MASH",
  "uid": "9c772f55-794a-57e6-9898-4e0416b2b327"
}